about
Lapatinib for metastatic breast cancer overexpressing HER2Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasPharmacodynamic modeling of adverse effects of anti-cancer drug treatmentConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and ManagementExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways.Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinomaPredicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.A case of trastuzumab-associated cardiomyopathy presenting as an acute coronary syndrome: acute trastuzumab cardiotoxicityCardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast CenterAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Chemotherapy-induced cardiomyopathy in breast cancer patients.Trastuzumab use in breast cancer: clinical issues.The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab.Trastuzumab-based combination therapy for breast cancer.Serum troponins as biomarkers of drug-induced cardiac toxicity.Dilated cardiomyopathy following trastuzumab chemotherapy.Clinical vignettes: integrated care of cancer patients by oncologists and cardiologistsCardiac toxicity of high-dose chemotherapy.Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer.The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferationPolymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.A specified therapeutic window for neuregulin-1 to regenerate neonatal heart muscleMolecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeuticsRole of the bradykinin B2 receptor in a rat model of local heart irradiation.Cardiac dysfunction associated with trastuzumab.Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancerLapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged SwordAntibody Therapeutics in Oncology.Heme oxygenase-1 regulates mitochondrial quality control in the heart.Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.Cardiac side effects of trastuzumab in breast cancer patients - single centere experiences.
P2860
Q24203605-B410D5DC-2F6F-4DD4-A323-6D3D8684C722Q24813451-E7821745-D37B-46F2-93F3-EA6E13613444Q26766318-4F21B77F-5AA4-46B6-A0FF-24CD8798E1D0Q26830569-BD99852C-C983-4989-B43E-21C56C453DBDQ27343148-2FF5C7A8-BA81-4752-9B69-ABB1DD7C9E16Q28068290-638D3EB6-E651-42EF-B223-98469743BA63Q30401812-48CCD019-A862-41DE-8BA7-7514CF1C925FQ30402943-CCDB4591-C5F7-4A87-BE75-9A8CE53F2432Q30593372-32006607-C36B-4813-B8E3-60E12996D3C8Q33293618-1DDED87A-16CB-448D-821A-AC8B77B3A59CQ33421127-EFDF8AF7-4D15-4B46-99CD-3BDBDD0148CFQ33511035-F78F9A83-0A74-45E6-8D03-B65E2B649707Q33559603-03100CE2-DDCC-42BE-9B35-869F098C2854Q33724456-C4520E96-EE8D-4604-AC78-B063997BDFACQ33800955-CF6C9AFD-9B85-46C0-8626-9A6744D9EB7EQ34042768-B974324F-5712-4780-BCB2-C8853B1053A0Q34049037-DEECFB3E-55C5-4B3D-B93C-06EF2DB40977Q34095827-DD932C22-1F26-4C3B-8B1E-4A205321948FQ34621237-7A9DF4E2-91D4-41CE-9AE8-80A3861D4F3CQ35039495-2DE3E5CA-0D4A-4595-A349-709A36651A24Q35582848-367CAC47-D284-491B-AD9B-848ADED2A534Q35609686-68EC9237-72BB-4EC8-BBF1-618E450F6C8AQ35624619-065019B5-58ED-4A2F-9340-84F02B670C90Q35732533-7F7B535C-6CEA-4F0B-A3AA-57533F06EA91Q35878473-522C4DA7-0FE6-4284-B5D4-1737D2748938Q35949084-53E929D9-31E6-426B-82CC-D0EE75319FEFQ36041152-76FC4D29-085B-44D5-A5A1-0533C0FDDB94Q36042588-306AFFFE-92F7-434A-B69F-C22B8D5A7AA7Q36191573-72B2DA8D-22EF-49DE-8B1A-85E7E08EB26BQ36204959-717CF280-1DE7-493C-B9BB-53AD8994C6DDQ36396421-D19EE2B7-ED7F-48F0-A8B5-D4DDEBF0C57EQ36552117-8D59CA40-C9E8-4117-B281-672A021C190FQ36565032-D8544F61-D44D-49CC-975E-C38D7143E1D5Q36673717-1C3AF85E-8C99-4508-A6F3-3F2F1EF058E3Q36717363-E4DD3E1B-E289-4D71-B66F-EB6C38C4CF6AQ36721511-8EF569AD-FCC6-4DF7-8E62-47A875135748Q36791878-31AF25E8-38FB-4DBF-A61B-B313847FC045Q36819774-A031D7FB-AFE9-4F8C-947A-26F5ACD2E82BQ36828128-C63228CE-F005-40ED-9B89-42C847419737Q36936807-D63BCEB8-02DA-4DBB-8372-D1E8A7BD6528
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Trastuzumab-associated cardiotoxicity.
@ast
Trastuzumab-associated cardiotoxicity.
@en
Trastuzumab-associated cardiotoxicity.
@nl
type
label
Trastuzumab-associated cardiotoxicity.
@ast
Trastuzumab-associated cardiotoxicity.
@en
Trastuzumab-associated cardiotoxicity.
@nl
prefLabel
Trastuzumab-associated cardiotoxicity.
@ast
Trastuzumab-associated cardiotoxicity.
@en
Trastuzumab-associated cardiotoxicity.
@nl
P2860
P356
P1433
P1476
Trastuzumab-associated cardiotoxicity.
@en
P2093
Deborah L Keefe
P2860
P304
P356
10.1002/CNCR.10854
P407
P577
2002-10-01T00:00:00Z